You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Tapentadol extended release in the management of peripheral diabetic neuropathic pain
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, January 2015
|
| DOI | 10.2147/tcrm.s32193 |
| Pubmed ID | |
| Authors |
Nalini Vadivelu, Alice Kai, Benjamin Maslin, Gopal Kodumudi, Aron Legler, Jack M Berger |
| Abstract |
Tapentadol, a μ-opioid agonist and norepinephrine reuptake inhibitor, has been found to be an effective medication for a wide variety of chronic pain conditions, including back pain, cancer-related pain, and arthritic pain. It has also been found to have fewer gastrointestinal side effects than more traditional opioid-based therapies. More recently, tapentadol extended release has been demonstrated to be effective in the management of painful diabetic neuropathy, an often debilitating condition affecting approximately one-third of all patients with diabetes. This review highlights the most up-to-date basic and clinical studies by focusing on the mechanisms of action of tapentadol and its clinical efficacy, especially with regard to painful diabetic neuropathy. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 25% |
| Colombia | 1 | 13% |
| United States | 1 | 13% |
| Canada | 1 | 13% |
| Australia | 1 | 13% |
| Unknown | 2 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 88% |
| Scientists | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 70 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 14% |
| Researcher | 6 | 9% |
| Student > Ph. D. Student | 6 | 9% |
| Student > Doctoral Student | 6 | 9% |
| Other | 5 | 7% |
| Other | 17 | 24% |
| Unknown | 20 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 34% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Unspecified | 4 | 6% |
| Nursing and Health Professions | 3 | 4% |
| Immunology and Microbiology | 2 | 3% |
| Other | 6 | 9% |
| Unknown | 26 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2015.
All research outputs
#6,528,938
of 25,374,647 outputs
Outputs from Therapeutics and Clinical Risk Management
#317
of 1,323 outputs
Outputs of similar age
#80,452
of 359,538 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#11
of 20 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,538 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.